Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
Key Highlights
- ➤Six Veracyte genomic-test studies scheduled for presentation at ESMO 2026
- ➤Decipher Prostate to provide first evidence predicting abiraterone benefit in very high-risk nonmetastatic disease
- ➤OPTIMA analysis evaluates economics of Prosigna-guided chemotherapy decisions after two years
- ➤Presentations span treatment selection and risk assessment across prostate, breast and bladder cancers
Expert Statements
Phillip Febbo, Chief scientific and medical officer of Veracyte
“The research being presented at ESMO reflects how understanding a tumor’s biology can inform decisions across cancer care.”
Phillip Febbo, Chief scientific and medical officer of Veracyte
“The Decipher Prostate study will provide the first evidence that the test predicts benefit from adding abiraterone to treatment for patients with clinically very high-risk disease.”
Phillip Febbo, Chief scientific and medical officer of Veracyte
“Alongside the OPTIMA economic analysis and new bladder cancer research, these studies address questions that matter to patients and clinicians.”
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that six studies involving its genomic tests will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The presentations span treatment selection and risk assessment in prostate and bladder cancer, as well as a late-breaking health economic analysis from the Phase III landmark OPTIMA breast cancer trial.
A prostate cancer oral presentation will provide the first evidence that the Decipher Prostate test predicts benefit from adding abiraterone to androgen deprivation therapy for patients with clinically very high-risk, nonmetastatic disease. The findings extend Decipher’s predictive evidence into another treatment setting and build on its established role in prostate cancer risk stratification and treatment benefit. A separate oral presentation will report a within-trial economic analysis of Prosigna-guided chemotherapy decisions in OPTIMA.
Get started
Create a free account to read the full story.